Hemophilia More Prevalent Than Previously Estimated
|
By HospiMedica International staff writers Posted on 01 Oct 2019 |
|
A new study reveals that over 1,125,000 men around the world have inherited hemophilia, three times more than previously estimated.
Researchers at McMaster University (Hamilton, ON, Canada), the World Federation of Hemophilia (WFH; Montréal, Canada), and other institutions conducted a random-effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom in order to estimate the prevalence and prevalence at birth of male patients with hemophilia A or B in proportion to total male population, life expectancy disadvantage as related to prevalence at birth, and the expected number of patients worldwide.
The results revealed a prevalence of hemophilia A of 17.1 cases per 100,000 males for all severities of hemophilia, six cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, five cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage (in high-income countries) is thus 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The study was published on September 10, 2019, in Annals of Internal Medicine.
“The expected number of patients with hemophilia worldwide is 1,125,000, of whom 418,000 should have severe hemophilia,” said lead author Professor Alfonso Iorio, MD, PhD, director of the Hamilton-Niagara hemophilia program at McMaster University. “Knowing how many patients are out there will enable health care systems to estimate the resources needed to treat the disease, and enable drug manufacturers to increase the investment in research to match the demand of a patient population three times larger than we previously thought.”
Hemophilia, which is found almost only in men, is caused by a genetic defect. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
McMaster University
World Federation of Hemophilia
Researchers at McMaster University (Hamilton, ON, Canada), the World Federation of Hemophilia (WFH; Montréal, Canada), and other institutions conducted a random-effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom in order to estimate the prevalence and prevalence at birth of male patients with hemophilia A or B in proportion to total male population, life expectancy disadvantage as related to prevalence at birth, and the expected number of patients worldwide.
The results revealed a prevalence of hemophilia A of 17.1 cases per 100,000 males for all severities of hemophilia, six cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, five cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage (in high-income countries) is thus 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The study was published on September 10, 2019, in Annals of Internal Medicine.
“The expected number of patients with hemophilia worldwide is 1,125,000, of whom 418,000 should have severe hemophilia,” said lead author Professor Alfonso Iorio, MD, PhD, director of the Hamilton-Niagara hemophilia program at McMaster University. “Knowing how many patients are out there will enable health care systems to estimate the resources needed to treat the disease, and enable drug manufacturers to increase the investment in research to match the demand of a patient population three times larger than we previously thought.”
Hemophilia, which is found almost only in men, is caused by a genetic defect. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
McMaster University
World Federation of Hemophilia
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiofrequency Generator
GX1
Medical Adhesive
MED 5570U
Latest Critical Care News
- Wearable Sweat Test Simplifies Cystic Fibrosis Diagnosis
- New Risk Calculator Identifies Heart Disease Earlier in Postpartum Women
- New Soft Optical Sensor Advances Heart and Brain Activity Mapping
- AI System Stabilizes Oxygen Levels More Reliably Than Standard Care
- Radiation-Free Cardiac Catheterization Improves Care for Children
- Simple Triage Protocol Reduces Emergency Department Length of Stay
- ECG-Based AI Detects Left Ventricular Dysfunction and Heart Failure
- Stretchable Hydrogel Electrodes Maintain Stable Signals During Movement
- New AI Wearable System Supports 24-Hour Sleep and Metabolic Regulation
- Sweat-Sensing Fingertip Patch Continuously Tracks Parkinson’s Medication Levels
- Postoperative Treatment Windows Enable Targeted Glioblastoma Therapy
- New Medical Masks and Gowns Support Protection Across Care Settings
- FDA Clears Software for Objective Assessment of Cognitive Function
- Stretchable Antenna Enables Reliable Wearable ECG Monitoring During Motion
- FDA Clears Noninvasive Test for Elevated Pulmonary Capillary Wedge Pressure
- FDA-Cleared Index Enables Pediatric-Specific Sedation Monitoring
Channels
Artificial Intelligence
view channel
AI Improves Bronchoscopic Navigation to Difficult-to-Reach Lung Lesions
Lung cancer is a leading cause of cancer mortality, and early detection improves survival. Reaching small, peripheral lung tumors for biopsy remains difficult because bronchoscopic navigation depends on... Read more
Collaborative AI System Improves Medical Diagnostic Accuracy
Hospitals face a persistent trade-off when deploying artificial intelligence for diagnosis. Broad “generalist” models handle many tasks but often lack disease-specific precision. Narrow “specialist” models... Read more
Surgical Techniques
view channel
Dual-Energy Mapping and Ablation Catheter Receives CE Mark for Ventricular Arrhythmias
Ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes, can be life-threatening and often occur in patients with advanced heart disease. Although catheter ablation... Read more
New Implant Provides Sustained Localized Therapy for Ovarian Cancer
Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Medical Imaging
view channel
MRI-Guided Ultrasound Method Advances Targeted Treatment of Gliomas
Gliomas, the most common primary brain tumors in adults, include glioblastoma, the deadliest form of brain cancer. Drug delivery is hampered by the brain’s blood-brain barrier, limiting treatment efficacy... Read more
AI Accelerates Individualized Dosimetry for Prostate Cancer Treatment
Radiopharmaceutical therapy is an injected cancer treatment that delivers radiation through the body while selectively targeting tumors. In prostate cancer, current dosing remains largely uniform despite... Read more
Health IT
view channel
Digital Symptom Monitoring Supports More Personalized Breast Cancer Care
Metastatic breast cancer, in which tumors spread to other organs, is incurable but increasingly managed with modern systemic therapies. As more treatments shift from hospital infusions to oral or at-home... Read more
Short Digital Training Program Improves Motor Function in Parkinson’s Disease
Parkinson's disease causes motor symptoms that interfere with movement and daily activities. Drug treatment is standard care, yet additional approaches are needed to target motor control.... Read more
Point of Care
view channel
Rapid Onsite Testing Reduces Emergency Department Transfers in Long-Term Care
Respiratory infections in long-term care residents frequently trigger emergency department transfers that strain hospital capacity and expose frail patients to additional risks. Turnaround delays from... Read more
New Brain Ultrasound Platform Enables Bedside Postoperative Imaging
Transporting postoperative patients for CT or MRI can create operational burdens, delays, and disruptions in care. Bedside visualization may help reduce transport demands, lower radiation exposure, and... Read more
Business
view channel
AI Software Combines Nodule Detection and Diagnosis for Lung Cancer Screening
Lung cancer remains the leading cause of cancer mortality, and screening programs rely on computed tomography to identify disease earlier when curative treatment is more likely. High patient volumes and... Read more
